Europe Point-of-Care Diagnostics Market to be Worth $12.98 Billion by 2030

Meticulous Research®-a leading global market research company, published a research report titled, 'Europe Point-of-Care Diagnostics Market by Application (Influenza, Pneumonia, TB, HAI, Salmonellosis, Hepatitis, HIV, COVID, Pregnancy, Glucose Monitoring, Hematology, Tumor Marker, Urinalysis), Platform (LFA, Molecular), Sample, and End User - Forecast to 2030.'

According to this latest publication from Meticulous Research®, the Europe point-of-care diagnostics market is expected to register a CAGR of 4.1% from 2023 to reach $12.98 billion by 2030. The increasing prevalence of infectious and chronic diseases, rising adoption of technical advancements to enhance the quality of point-of-care diagnostics, development of CLIA-waived PoC tests, and a growing number of in-house hospital laboratories opting for PoC diagnostics are the key factors driving the Europe point of care diagnostics market. In addition, healthcare professionals' increasing preference for POC tests over other lab tests and growing advanced healthcare infrastructure across European countries are expected to offer significant growth opportunities in the market. However, limited reimbursement policies and cost constraints are expected to restrain the growth of this market to some extent.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5650

Key Players:

The key players operating in the Europe point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), QuidelOrtho Corporation (U.S.), Sekisui Diagnostics, LLC. (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), and Nova Biomedical (U.S.).

Europe Point-of-Care Diagnostics Market: Future Outlook

The Europe point-of-care diagnostics market is segmented by offering (consumables, instruments, and software and services); platform (lateral flow assays, molecular diagnostics, and other platform); application (blood glucose monitoring, infectious disease testing [parasitic infections testing, blood-borne infections testing {Hepatitis, HIV, other blood-borne infections}, respiratory infections testing {Influenza, Pneumonia, COVID-19 testing, other respiratory infections testing}, healthcare-associated infection (HAI) testing, gastrointestinal infections testing {salmonellosis, E. Coli infections, other GI infections} other infectious diseases testing], tumor/cancer markers testing, pregnancy and fertility testing [pregnancy testing, fertility testing], cardiac marker/cardiac metabolism testing, cholesterol/lipid profile testing, coagulation testing [prothrombin time (PT/INR) testing, activated clotting time (ACT/APTT) testing, other coagulation testing], hematology, drugs of abuse testing, urinalysis, other POC testing); sample type (blood sample, nasopharyngeal swab, urine sample, saliva sample, other sample types); end user (home care/self-testing, hospitals, physician offices & ambulatory care settings, diagnostics laboratories, and other end users), and geography. The study also evaluates industry competitors and analyzes their market share at the country level.

Speak To Our Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5650

Among all the offerings in the report, the consumables segment is expected to account for the largest share of the point-of-care diagnostics market. Factors such as Recurrent use of consumables in the detection of various diseases through diagnostics, rise in product approvals, increased use of kits in healthcare settings, and technological advancements in ELISpot assay kits, direct-to-customer tests contribute to the large share of the kits & reagents segment.

Among all the platforms studied in the report, the molecular diagnostics segment is projected to grow fastest during the forecast period. The growing need for advanced diagnostic techniques, the widening applications of molecular detection tests in various fields, and product launches are the major factors contributing to the market's growth.

Among all the applications studied in the report, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the Europe point-of-care diagnostics market. The large market share of this segment is attributed to the rising prevalence of diabetes, new product launches, and the growing need for blood glucose monitoring. The major factors responsible for such a high incidence of diabetes are the lack of awareness and knowledge, physical inactivity, and the growing prevalence of obesity. Therefore, it is important to periodically monitor the blood glucose level to prevent further implications of diabetes.

Among all the sample types studied in the report, the blood sample type segment is expected to account for the highest CAGR during the forecast period. The growth of this segment is attributed to the availability of a large variety of tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.

Among all the end users studied in the report, the hospital segment is expected to account for the largest share of the Europe point-of-care diagnostics market in 2023. As hospitals perform various tests to diagnose various medical conditions, the increasing healthcare expenditure worldwide is expected to boost the point-of-care diagnostics market. Point-of-care (PoC) devices are widely used in various areas of the hospital, including the emergency department (ED), intensive care unit (ICU), operating room/reanimation, delivery room/neonatal ward, CT scanning/invasive radiology, diabetic care ward, and dialysis unit. PoC testing is particularly prevalent in the ED, as it enables rapid confirmation of diagnoses, allowing for quick treatment initiation and reducing patient wait times.

Quick Buy @ https://www.meticulousresearch.com/Checkout/26149386

Among all the countries studied in the report, Germany is expected to account for the largest share of the European point-of-care diagnostics market in 2023. The large market share of Germany is attributed to the rising prevalence of infectious diseases, the rising number of deaths associated with behavioral risk factors, and the growth in the country's aging population with a high incidence of chronic diseases are driving the growth of this market.

Key questions answered in the report:

What are the high-growth market segments regarding the offering, platform, applications, techniques, sample types, end user, and country?

What was the historical market for Europe's point-of-care diagnosis?

What are the market forecasts and estimates for 2023-2030?

What are the major drivers, restraints, challenges, and opportunities in the Europe point-of-care diagnostics market?

Who are the major players in the Europe point-of-care diagnostics market?

About Us:
We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition. Through our mixed bag of research offerings - syndicated research, custom research, and analyst engagement - we enable smart decision making to enhance business performance for global organizations. Our focus is also on finding answers to the challenging questions that global business leaders face on a daily basis. Each year, we deliver more than 300 syndicate studies and 60+ consulting projects across eight industry verticals in 20+ geographic markets.

Contact Us:
Meticulous Market Research Pvt Ltd
Office No-202, 203,204,205,206
2nd Floor, Pushpak Business Hub,
Wakad, Pimpri-Chinchwad,
411057, India.
Phone: +9102066394988
CIN- U93000PN2013PTC149455

This release was published on openPR.